Pieris Pharmaceuticals to Host Third Quarter 2018 Investor Call and Corporate Update on November 7, 2018
31 Octobre 2018 - 1:00PM
Pieris Pharmaceuticals, Inc. (NASDAQ:
PIRS), a biotechnology company advancing novel biotherapeutics
through its proprietary Anticalin® technology platform for
cancer, respiratory and other diseases, announced today that it
will host a third quarter 2018 investor call on Wednesday, November
7, 2018 at 8:00 AM (EDT) to discuss financial results and provide a
corporate update.
To access the call, participants may dial 877-407-8920 (US &
Canada) or 412-902-1010 (International) at least 10 minutes prior
to the start of the call.
An archived replay of the call will be available for 30 days by
dialing 877-660-6853 (Toll Free US & Canada) or 201-612-7415
(International) and providing the Conference ID #13661472.
About Pieris Pharmaceuticals Pieris is a
clinical-stage biotechnology company that discovers and develops
Anticalin protein-based drugs to target validated disease pathways
in a unique and transformative way. Our pipeline includes
immuno-oncology multi-specifics tailored for the tumor
microenvironment, an inhaled Anticalin protein to treat
uncontrolled asthma and a half-life-optimized Anticalin protein to
treat anemia. Proprietary to Pieris, Anticalin proteins are a novel
class of therapeutics validated in the clinic and by partnerships
with leading pharmaceutical companies. Anticalin® is a registered
trademark of Pieris. For more information, visit
www.pieris.com.
Forward Looking Statements This press release
contains forward-looking statements as that term is defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Statements in this press release
that are not purely historical are forward-looking statements. Such
forward-looking statements include, among other things, references
to novel technologies and methods and our business and product
development plans, including the advancement of our proprietary and
co-development programs into and through the clinic. Actual results
could differ from those projected in any forward-looking statements
due to numerous factors. Such factors include, among others, our
ability to raise the additional funding we will need to continue to
pursue our business and product development plans; the inherent
uncertainties associated with developing new products or
technologies and operating as a development stage company; our
ability to develop, complete clinical trials for, obtain approvals
for and commercialize any of our product candidates, including our
ability to recruit and enroll patients in our studies; our ability
to address the requests of the FDA; competition in the industry in
which we operate and market conditions. These forward-looking
statements are made as of the date of this press release, and we
assume no obligation to update the forward-looking statements, or
to update the reasons why actual results could differ from those
projected in the forward-looking statements, except as required by
law. Investors should consult all of the information set forth
herein and should also refer to the risk factor disclosure set
forth in the reports and other documents we file with the SEC
available at www.sec.gov, including without limitation the
Company's Annual Report on Form 10-K for the fiscal year ended
December 31, 2017 and the Company's Quarterly Reports on Form
10-Q.
Company Contact: Allan Reine SVP & Chief
Financial Officer +1 857 444 4276 reine@pieris.com
Investor Relations Contact: Maria Kelman Director, Investor
Relations +1 857 362 9635 kelman@pieris.com
Pieris Pharmaceuticals (NASDAQ:PIRS)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Pieris Pharmaceuticals (NASDAQ:PIRS)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024